GH Research (GHRS) Competitors $12.53 -0.35 (-2.72%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GHRS vs. MIRM, GMTX, BLTE, ARWR, CGON, HRMY, ARQT, JANX, TVTX, and AGIOShould you be buying GH Research stock or one of its competitors? The main competitors of GH Research include Mirum Pharmaceuticals (MIRM), Gemini Therapeutics (GMTX), Belite Bio (BLTE), Arrowhead Pharmaceuticals (ARWR), CG Oncology (CGON), Harmony Biosciences (HRMY), Arcutis Biotherapeutics (ARQT), Janux Therapeutics (JANX), Travere Therapeutics (TVTX), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry. GH Research vs. Mirum Pharmaceuticals Gemini Therapeutics Belite Bio Arrowhead Pharmaceuticals CG Oncology Harmony Biosciences Arcutis Biotherapeutics Janux Therapeutics Travere Therapeutics Agios Pharmaceuticals GH Research (NASDAQ:GHRS) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, community ranking, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership. Does the MarketBeat Community favor GHRS or MIRM? Mirum Pharmaceuticals received 102 more outperform votes than GH Research when rated by MarketBeat users. However, 76.92% of users gave GH Research an outperform vote while only 75.86% of users gave Mirum Pharmaceuticals an outperform vote. CompanyUnderperformOutperformGH ResearchOutperform Votes3076.92% Underperform Votes923.08% Mirum PharmaceuticalsOutperform Votes13275.86% Underperform Votes4224.14% Do analysts rate GHRS or MIRM? GH Research currently has a consensus target price of $30.86, suggesting a potential upside of 146.27%. Mirum Pharmaceuticals has a consensus target price of $58.20, suggesting a potential upside of 23.67%. Given GH Research's higher probable upside, analysts plainly believe GH Research is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Do insiders & institutionals have more ownership in GHRS or MIRM? 56.9% of GH Research shares are held by institutional investors. 41.6% of GH Research shares are held by company insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to GHRS or MIRM? In the previous week, Mirum Pharmaceuticals had 10 more articles in the media than GH Research. MarketBeat recorded 12 mentions for Mirum Pharmaceuticals and 2 mentions for GH Research. Mirum Pharmaceuticals' average media sentiment score of 0.52 beat GH Research's score of 0.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is GHRS or MIRM more profitable? GH Research has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -31.69%. GH Research's return on equity of -20.29% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -20.29% -19.49% Mirum Pharmaceuticals -31.69%-41.22%-14.81% Which has more risk and volatility, GHRS or MIRM? GH Research has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Which has higher valuation and earnings, GHRS or MIRM? GH Research has higher earnings, but lower revenue than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$35.59M-$0.75-16.71Mirum Pharmaceuticals$336.89M6.85-$163.41M-$1.85-25.44 SummaryGH Research and Mirum Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get GH Research News Delivered to You Automatically Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GHRS vs. The Competition Export to ExcelMetricGH ResearchPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$651.91M$6.99B$5.68B$8.32BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-15.867.2324.5519.25Price / SalesN/A230.77395.7394.10Price / CashN/A65.6738.1634.64Price / BookN/A6.617.064.46Net Income-$35.59M$142.13M$3.19B$247.07M7 Day Performance18.21%2.79%1.49%3.06%1 Month Performance7.28%2.70%5.87%-2.85%1 Year Performance18.77%-4.42%14.94%4.64% GH Research Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GHRSGH Research2.3562 of 5 stars$12.53-2.7%$30.86+146.3%+19.6%$651.91MN/A-15.8610MIRMMirum Pharmaceuticals3.258 of 5 stars$45.15+2.0%$58.20+28.9%+79.9%$2.21B$336.89M-22.35140GMTXGemini TherapeuticsN/A$51.02-2.7%N/A-13.8%$2.21BN/A-51.0230Positive NewsBLTEBelite Bio2.1568 of 5 stars$67.81+0.5%$96.33+42.1%+52.3%$2.16BN/A-61.0910Gap DownARWRArrowhead Pharmaceuticals3.6511 of 5 stars$15.60+1.6%$41.44+165.7%-43.0%$2.14B$2.50M-3.02400CGONCG Oncology1.8411 of 5 stars$27.67-0.5%$63.88+130.8%-29.6%$2.10B$684,000.000.0061Analyst ForecastNews CoverageHRMYHarmony Biosciences4.2906 of 5 stars$34.32+4.9%$53.11+54.8%+2.8%$1.97B$714.73M16.27200News CoverageARQTArcutis Biotherapeutics1.2485 of 5 stars$16.42+12.3%$18.80+14.5%+79.9%$1.95B$196.54M-9.17150Positive NewsGap UpHigh Trading VolumeJANXJanux Therapeutics3.54 of 5 stars$31.51+2.7%$92.44+193.4%-19.7%$1.86B$10.59M-26.9330Positive NewsTVTXTravere Therapeutics2.9731 of 5 stars$20.87+5.8%$30.62+46.7%+170.2%$1.85B$233.18M-5.09460Positive NewsAGIOAgios Pharmaceuticals4.3534 of 5 stars$31.99+3.4%$56.57+76.8%+8.1%$1.83B$36.50M2.82390Positive News Remove Ads Related Companies and Tools Related Companies Mirum Pharmaceuticals Alternatives Gemini Therapeutics Alternatives Belite Bio Alternatives Arrowhead Pharmaceuticals Alternatives CG Oncology Alternatives Harmony Biosciences Alternatives Arcutis Biotherapeutics Alternatives Janux Therapeutics Alternatives Travere Therapeutics Alternatives Agios Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GHRS) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
